The effect of P2 receptor antagonists and ATPase inhibition on sympathetic purinergic neurotransmission in the guinea-pig isolated vas deferens

被引:22
作者
Sneddon, P
Westfall, TD
Todorov, LD
Todorova, SM
Westfall, DP
Nickel, P
Kennedy, C
机构
[1] Univ Strathclyde, Strathclyde Inst Biomed Sci, Dept Physiol & Pharmacol, Glasgow G4 0NR, Lanark, Scotland
[2] Univ Nevada, Sch Med, Dept Pharmacol, Reno, NV 89557 USA
[3] Univ Bonn, Dept Pharmaceut Chem, D-53121 Bonn, Germany
关键词
ATP; ARL; 67156; nucleoside triphosphatase; purinergic; vas deferens; NF023; P-5-P; PPADS;
D O I
10.1038/sj.bjp.0703163
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Intracellular microelectrodes were used to record the transmembrane potential and excitatory junction potentials (e.j.p.s) produced by sympathetic nerve stimulation (1 Hz) in smooth muscle cells of the guinea-pig isolated vas deferens. 2 The symmetrical 3'-urea of 8-(benzamido)naphthalene-1,3,5-trisulphonic acid (NF023) produced a concentration-dependent inhibition of e.j.p. magnitude (IC50 = 4.8 x 10(-6) M), but had no effect on the resting membrane potential of the smooth muscle cells. 3 Pyridoxal-5-phosphate (P-5-P) also depressed e.j.p. magnitude in a concentration-dependent manner, but was less potent than NF023 (IC50 = 2.2 x 10(-5) M). At 10(-4) M and above P-5-P significantly depolarized the smooth muscle cells. 4 The nucleoside triphosphatase inhibitor 6-N,N-diethyl-D-beta,gamma-dibromomethyleneATP (ARL 67156) (5 x 10(-5) M) significantly increased e.j.p. amplitude. ARL 67156 (10(-4) M) further increased e.j.p. amplitude such that they often reached threshold for initiation of action potentials, causing muscle contraction and expulsion of the recording electrode. 5 After reduction of e.j.p.s by NF023 or P-5-P (both 10(-5) M), subsequent co-addition of ARL 67156 (10(-4) M) significantly increased their magnitude. 6 The overflow of endogenous ATP evoked by field stimulation of sympathetic nerves (8 Hz, 1 min) was measured by HPLC and flurometric detection. ARL 67156 (10(-4) M) enhanced ATP overflow by almost 700% compared to control. 7 We conclude that for electrophysiological studies NF023 is preferable to other P2X receptor antagonists such as pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS), suramin or P-5-P. Furthermore, breakdown of endogenous ATP by nucleoside triphosphatases is an important modulator of purinergic neurotransmission in the guinea-pig vas deferens.
引用
收藏
页码:1089 / 1094
页数:6
相关论文
共 29 条
  • [1] EFFECTS OF ALPHA,BETA-METHYLENE ATP ON BIPHASIC RESPONSES OF RAT VAS-DEFERENS
    AMOBI, N
    SMITH, ICH
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1987, 133 (01) : 75 - 82
  • [2] P-2-purinoceptor antagonists .3. Blockade of P-2-purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin
    Bultmann, R
    Wittenburg, H
    Pause, B
    Kurz, G
    Nickel, P
    Starke, K
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1996, 354 (04) : 498 - 504
  • [3] BURNSTOCK G, 1972, PHARMACOL REV, V24, P509
  • [4] BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1
  • [5] PHARMACOLOGICAL-ANALYSIS AND BIOCHEMICAL-ANALYSIS OF FPL-67156, A NOVEL, SELECTIVE INHIBITOR OF ECTO-ATPASE
    CRACK, BE
    POLLARD, CE
    BEUKERS, MW
    ROBERTS, SM
    HUNT, SF
    INGALL, AH
    MCKECHNIE, KCW
    IJZERMAN, TP
    LEFF, P
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1995, 114 (02) : 475 - 481
  • [6] EVANS RJ, 1995, MOL PHARMACOL, V48, P178
  • [7] Evidence that P2Y4 nucleotide receptors are involved in the regulation of rat aortic smooth muscle cells by UTP and ATP
    Harper, S
    Webb, TE
    Charlton, SJ
    Ng, LL
    Boarder, MR
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1998, 124 (04) : 703 - 710
  • [8] KHAKH BS, 1995, BRIT J PHARMACOL, V115, pP2
  • [9] Design and pharmacology of selective P-2-purinoceptor antagonists
    Lambrecht, G
    [J]. JOURNAL OF AUTONOMIC PHARMACOLOGY, 1996, 16 (06): : 341 - 344
  • [10] INVESTIGATION OF THE ACTIONS OF PPADS, A NOVEL P-2X-PURINOCEPTOR ANTAGONIST, IN THE GUINEA-PIG ISOLATED VAS-DEFERENS
    MCLAREN, GJ
    LAMBRECHT, G
    MUTSCHLER, E
    BAUMERT, HG
    SNEDDON, P
    KENNEDY, C
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1994, 111 (03) : 913 - 917